Geode Capital Management LLC Sells 34,189 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Geode Capital Management LLC lowered its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 1.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,664,424 shares of the biopharmaceutical company's stock after selling 34,189 shares during the quarter. Geode Capital Management LLC owned approximately 2.23% of Catalyst Pharmaceuticals worth $52,979,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. GAMMA Investing LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 62.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 681 shares during the last quarter. nVerses Capital LLC bought a new stake in Catalyst Pharmaceuticals in the third quarter worth $50,000. Larson Financial Group LLC boosted its position in Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company's stock valued at $60,000 after buying an additional 2,994 shares during the period. Meeder Asset Management Inc. bought a new position in shares of Catalyst Pharmaceuticals during the second quarter valued at about $70,000. Finally, Quantbot Technologies LP purchased a new position in shares of Catalyst Pharmaceuticals in the third quarter worth about $151,000. 79.22% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on CPRX. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Stephens started coverage on Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an "overweight" rating and a $35.00 price objective for the company. Finally, Truist Financial lifted their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a research note on Monday, November 11th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $31.14.

Catalyst Pharmaceuticals Price Performance

NASDAQ:CPRX traded up $0.33 during trading hours on Monday, hitting $21.60. The company had a trading volume of 594,831 shares, compared to its average volume of 1,167,624. The stock has a 50-day moving average price of $21.79 and a 200 day moving average price of $19.41. The company has a market capitalization of $2.58 billion, a PE ratio of 18.31, a price-to-earnings-growth ratio of 3.35 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a 52 week low of $13.12 and a 52 week high of $24.27.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the sale, the insider now directly owns 686,996 shares in the company, valued at $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Gary Ingenito sold 12,000 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the completion of the transaction, the insider now owns 51,391 shares of the company's stock, valued at approximately $1,167,603.52. This trade represents a 18.93 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 79,500 shares of company stock valued at $1,754,140. Company insiders own 11.00% of the company's stock.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.